It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Marc Tessier-Lavigne Biography and Net Worth

Director of Regeneron Pharmaceuticals

Marc Tessier-Lavigne, Ph.D., has been a Director of the Company since November 2011. Dr. Tessier-Lavigne was appointed as the President of Stanford University in September 2016. From March 2011 to August 2016, he served as the President of The Rockefeller University. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, which he joined in 2003. He was a professor at Stanford from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Tessier-Lavigne, a leader in the field of brain development, is a member of the National Academy of Sciences and its Institute of Medicine and a fellow of the Royal Societies of the United Kingdom and Canada.

What is Marc Tessier-Lavigne's net worth?: The estimated net worth of Marc Tessier-Lavigne is at least $1.39 billion as of November 23rd, 2022. Dr. Tessier-Lavigne owns 1,870,356 shares of Regeneron Pharmaceuticals stock worth more than $1,390,329,133 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Tessier-Lavigne may own. Learn More about Marc Tessier-Lavigne's net worth.
How do I contact Marc Tessier-Lavigne?: The corporate mailing address for Dr. Tessier-Lavigne and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Marc Tessier-Lavigne's contact information.
Has Marc Tessier-Lavigne been buying or selling shares of Regeneron Pharmaceuticals?: Marc Tessier-Lavigne has not been actively trading shares of Regeneron Pharmaceuticals in the last ninety days. Most recently, Marc Tessier-Lavigne sold 3,612 shares of the business's stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $718.00, for a transaction totalling $2,593,416.00. Following the completion of the sale, the director now directly owns 2,269 shares of the company's stock, valued at $1,629,142. Learn More on Marc Tessier-Lavigne's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 28 times. They sold a total of 108,095 shares worth more than $105,638,222.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Marc Tessier-Lavigne Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/3/2022	Sell	3,612	$718.00	$2,593,416.00	2,269
9/30/2022	Sell	3,428	$698.00	$2,392,744.00	2,269
3/21/2022	Sell	7,439	$690.00	$5,132,910.00
3/16/2022	Sell	4,361	$675.00	$2,943,675.00
12/9/2021	Sell	3,784	$665.00	$2,516,360.00
2/26/2015	Sell	3,000	$421.95	$1,265,850.00

Marc Tessier-Lavigne Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $743.35

$736.01

$750.69

50 Day Range

MA: $961.76

$743.35

$1,164.46

2 Week Range

Now: $743.35

$736.01

$1,211.20

Volume

654,394 shs

Average Volume

860,893 shs

Market Capitalization

$81.69 billion

P/E Ratio

18.40

Dividend Yield

N/A

Beta

0.15

Tesla Execs are Freaking Out

From Angel Publishing | Ad

Click here to get the details.